Aliskiren in Combination with Losartan Reduces Albuminuria Independent of Baseline Blood Pressure in Patients with Type 2 Diabetes and Nephropathy | Zendy

Frederik Persson | Zendy; Julia B. Lewis | Zendy; Edmund J. Lewis | Zendy; Peter Rossing | Zendy; Norman K. Hollenberg | Zendy; HansHenrik Parving | Zendy

Open Access

Aliskiren in Combination with Losartan Reduces Albuminuria Independent of Baseline Blood Pressure in Patients with Type 2 Diabetes and Nephropathy

Author(s) -

Frederik Persson,

Julia B. Lewis,

Edmund J. Lewis,

Peter Rossing,

Norman K. Hollenberg,

HansHenrik Parving

Publication year - 2011

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.07590810

Subject(s) - medicine , albuminuria , losartan , diabetic nephropathy , blood pressure , type 2 diabetes , aliskiren , urology , diabetes mellitus , irbesartan , empagliflozin , nephropathy , cardiology , endocrinology , angiotensin ii , renin–angiotensin system

Elevated BP contributes to development and progression of proteinuria and decline in renal function in patients with type 2 diabetes. Our post hoc analysis assessed the baseline BP influence on the antiproteinuric effect in the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research